The thyroid sodium-iodide symporter (NIS) is responsible for iodide concentrating ability within thyroid follicular cells. We sought to develop monoclonal antibodies against human NIS (hNIS) for use as reagents in structure-function studies of the protein, as well as potential tools in the assessment of NIS expression in benign and malignant thyroid tissues. Synthetic peptides corresponding to the second ExMD and to the carboxy-terminal ExMD of hNIS were produced and utilized as antigens to develop monoclonal antibodies, which were tested by Western blotting using membranes prepared from COS-7 cells transiently transfected with a pcDNA3 plasmid containing the gene for the full-length hNIS, or a control vector. Western blotting showed a major band with molecular weight (MW) of approximately 97 kDa and several minor bands with MW of approximately 160 kDa, 68 kDa, 30 kDa, and 15 kDa, all specific for hNIS-transfected cells. Immunohistochemistry was performed in various types of thyroid tissues and nonthyroidal tissues, using the monoclonal antibodies. Strong immunostaining was observed in Graves' tissue, intermediate staining in papillary and follicular thyroid cancer, and no staining in Hü rthle cell cancer or in nonthyroidal tissue. The staining was specific for the follicular epithelium in each of the tissues and was most intense in the basolateral portion of the cell membrane. Overall, our observations indicate that the monoclonal antibodies are specific for hNIS and will be invaluable reagents for investigating the role of NIS in thyroid disease. (J Clin Endocrinol Metab 84: 2957-2962,1999 
D
ISEASES of the thyroid gland represent some of the most common disorders of American women. Many of these diseases are autoimmune disorders, which are characterized by the presence of autoantibodies against specific thyroid proteins, such as thyroid peroxidase, thyroglobulin, and the TSH receptor (1) . Recently a new thyroid protein that is important in the physiology of thyroid hormonogenesis, the thyroid iodide transporter (2) , has been cloned and characterized. This membrane-bound glycoprotein functions as a sodium iodide symporter (NIS) and, when expressed in a suitable cell system, results in iodine-trapping ability with kinetics similar to that of the native protein in thyroid cells (2) . Although originally described with 12 membrane-spanning segments separated by 13 extramembranous domains (ExMD), one of these ExMD lying at each end of the molecule, a newer model has been recently proposed, containing 13 membrane-spanning segments and 14 ExMD (3) (Fig. 1) .
Through molecular cloning techniques, the sequence of the human NIS (hNIS) has become available (4) . The importance of the characterization and study of NIS is related to its role in thyroid function, the pathogenesis of thyroid disease, and its expression or lack thereof, in thyroid malignancies. It is the activity of this molecule that makes possible the most specific form of therapy for differentiated thyroid cancer, radioiodine. Expressed predominantly in thyroid tissue, it has also been suggested that NIS may represent an autoantigen in autoimmune disease of the thyroid (5).
To study the structure, function, and expression of NIS in vitro, highly specific antibodies are needed as a reagent. Because NIS has been cloned and sequenced, it is possible to use synthetic peptides containing antigenic sequences to develop monoclonal antibodies for these purposes. This report describes the development of such reagents and initial studies of NIS expression in thyroid tissues using them.
Materials and Methods

Peptide production
Peptides corresponding to the ExMD of hNIS (hNIS-2), amino acids 37-54 (ARGGQRSAEDFFTLGGRRL), and to the carboxy terminus (hNIS-14f), amino acids 625-643 (SWTPCVGHDGGRDQQETNL), were generated by solid phase synthesis and subsequently purified by highperformance liquid chromatography on a C-18 column as described (6) . The purity and composition of the peptides was confirmed by amino acid analysis and mass spectrometry. The resulting peptides were coupled to the carrier molecule KLH, at a concentration of 5 mg/mL (7).
Immunizations
The peptides were emulsified in equal ratios of Freund's Complete Adjuvant (FCA) and 0.9% saline to a final concentration of 100 g/mL. Two groups of five Balb C mice each were immunized subcutaneously with 50 g of the conjugated peptide and boosted with an equal dose twice at 3-week intervals. Ten days after each boost, the mice were bled and their sera tested by Enzyme-linked immunosorbent assay (ELISA) for relevant antibody activity to unconjugated peptide. A final boost was given on week 10 by iv injection of 100 g of the conjugated peptide diluted in 0.9% saline, to a final volume of 1 mL, in a tail vein of the mouse in each group with the highest antibody titer.
Monoclonal antibodies (MoAbs) production
B cell hybridomas were generated using spleen cells from immunized mice according to standard protocols (8) .
The studies and procedures were reviewed and approved by the Mayo Foundation Institutional Animal Care and Use Committee.
Enzyme-linked immunosorbent assay (ELISA)
Microtiter plates were coated with 10 g/mL of the free peptides (hNIS-2 and hNIS 14f) and incubated overnight at 4 C. nonspecific binding sites were blocked with 1% BSA in phosphate buffered salineTween-20 (PBS-T). Mouse sera diluted 1:1000 in PBS-T, or undiluted hybridoma supernatant media when screening clones, were added to each well. Alkaline phosphatase goat anti-mouse (GAM) (Sigma, St. Louis, MO) at 1:5000 dilution was used as the second stage antibody, and nitrophenyl phosphate substrate was used for detection. Optical density (OD) was read at 405 nm. Appropriate negative controls with nonimmune commercial mouse immunoglobulin G (IgG) (Sigma I 5381) at the same dilutions were performed with each assay. For positive control, a well coated with peptide hCG␣ and a monoclonal antibody (E512) (9) against this peptide was used.
The immunoglobulin class, subclass, and light chain type of the monoclonal antibodies were determined using a mouse hybridoma subtyping kit (Boehringer Ingelheim GmbH, Mannheim, Germany), according to instructions from the manufacturer.
Functional expression of hNIS in COS-7 cells
COS-7 cells were grown in DMEM (Life Technologies, Inc.) supplemented with 10% FBS, 1% glutamine, and 1% penicillin/streptomycin. Fresh media was replaced every other day until the cells reached approximately 75% confluency, at which time they were subcultured into 12 well plates, at a density of approximately 100,000 cells per well. These cells were transfected by the lipofectamine technique (Life Technologies, Inc.) with a pcDNA3 plasmid containing the gene for the full-length hNIS (FL-hNIS) (amino acids 1-643) (provided by Dr. S. Jhiang, Ohio State University) or the pcDNA3 vector only. Forty-eight hours after transfection, iodide uptake was assessed as previously described (10) .
Preparation of COS-7 membranes
Membranes from COS-7 cells were prepared by a modification of a previously described procedure (11) . In brief, the transfected cells were washed with PBS, harvested, and resuspended in ice-cold 250 mm sucrose, 10 mm hepes pH 7.5, 1 mm EDTA containing aprotinin (10 g/ mL), leupeptin (10 g/mL), and 1 mm phenylmethylsulfonyl fluoride. The samples were centrifuged twice at 500 ϫ g for 15 min at 4 C. (100 mm) was added to the resulting supernatant and shaken for 45 min at 4 C, and then centrifuged at 100,000 ϫ g for 15 min. The pellet obtained was resuspended in 500 L of a buffer containing 250 mm sucrose, 10 mm Hepes pH 7.5, 1 mm MgCl 2 , and aliquoted for future use. Protein content was quantitated using the Bio-Rad Laboratories, Inc. DC protein assay (Bio-Rad Laboratories, Inc. Hercules, CA), using BSA as standard.
Western blot analyses
Membrane samples were prepared for electrophoresis by addition of NuPAGE SDS sample buffer with reducing agent, (NuPAGE, Novex, San Diego, CA). The samples were then incubated in a 70-C water bath for 10 min, and 2 g membrane protein from cells transfected with FL-hNIS or control vector were loaded onto a 4 -12% acrylamide gradient gel. After electrophoresis, the proteins were transferred to nitrocellulose membranes by electroblotting at 25 mV for 1 h. Nonspecific binding sites were blocked with 5% milk in 20 mm TRIS pH 7.4, 137 mm NaCl, 0.1% Tween-20 (TBST) for 1 h. The membranes were then incubated for 2 h at room temperature with the various antibody preparations (initially all IgG clones from hNIS 2, and all of hNIS 14f) diluted 1:5000 with TBST. After washing 3 times with TBST, the membranes were incubated for 1 h with peroxidase-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, Inc., West Grave, PA) at a 1:5000 dilution, and subsequently the proteins were visualized with chemiluminescent detection reagents (Amersham Pharmacia Biotech, ECL, Buckinghamshire, England). The same procedure was repeated after preincubating the antibody preparations (MoAb hNIS 2-2 and MoAb hNIS 14f-6) overnight at the same dilutions, with excess (50 mcg) peptide (hNIS-2 and hNIS-14f) and with 1500 g of a membrane prepared from a CHO cell line permanently transfected with hNIS or the control vector as described above.
Immunostaining
Paraffin-embedded sections of normal thyroid gland, Graves diseasethyroid gland, papillary, follicular, and Hü rthle cell thyroid cancers (three tissue samples of each), as well as nonthyroidal tissue (skin, endometrium-three tissue sample of each) were stained by the immunoperoxidase method. The tissue sections were obtained from the archives of our pathology department and initially deparaffinized by serial passages in xylene and graded alcohol. Endogenous peroxidase activity was blocked by incubation of slides in a 50% by volume solution of 3% H 2 O 2 /methanol for 10 min. Subsequently, the slides were subjected to antigen retrieval with 10 mm citrate buffer steam for 30 min. Nonspecific binding sites were blocked by applying 5% normal goat serum (NGS) diluted in PBS/0.05% Tween-20 (PBS-T), and incubated at room temperature for 30 min. Primary antibody (hNIS14f-6), nonimmune commercial mouse IgG (for negative control), or thyroglobulin (for positive control) diluted 1:1000 in 1% NGS-PBS-T was added and slides incubated ϫ 1 hr at room temperature. Biotinylated goat-anti-mouse IgG at a 1:200 dilution was used as second-stage antibody, incubated for 20 min, followed by another incubation for 20 min with peroxidase-conjugated streptavidin (Dako Corp., Denmark) at a 1:300 dilution in the same buffer, and a final incubation for 15 min in 3-amino-9-ethyl-carbazole (AEC) substrate solution (Sigma). The slides were counterstained with hematoxylin and mounted using a glycerol gelatine previously warmed in a water bath.
Review of the records of patients (whose thyroid tissues are shown in fig. 5, below) showed that the Graves'disease patient had been treated with 2 weeks of Lugol's solution and 15 mg/day of methimazole before surgery. The thyroid cancer patients did not receive treatment with either thyroid hormone or radioiodine before the surgery.
Results
Mouse antibody titers
Ten days after the first boost, all mice had developed antibody titers, detectable even at a 1:3000 dilution of the serum, which increased further after boosting. The mouse with the highest titers against hNIS-2 had antibody titers at 1:1,000 dilution, which were, on average, 7.5 times the OD of   FIG. 3 Western blot of hNIS under reduced conditions using transfected COS-7 cell membranes. hNIS was identified as a major broad band of molecular weight (MW) ϳ97 kDa, and several minor bands of MW ϳ160 kDa, ϳ68 kDa, ϳ30 kDa, and ϳ15kDa.
the negative control at the same dilution (mean Ϯ sem) (1.106 Ϯ 0.016 vs 0.147 Ϯ 0.008), and the mouse with the highest antibody titers against hNIS-14f had titers at 1:1,000 dilution that were 5.9 times the OD of the negative control at the same dilution (1.123 Ϯ 0.009 vs. 0.19 Ϯ 0.025).
Production of monoclonal antibodies and isotyping
Seven distinct clones that recognized hNIS-2 were recovered after three rounds of cloning and subcloning. When isotyped, two of the antibodies were found to be IgM, (referred to as MoAbs no. 2-7 and no. 2-9), whereas the other five were IgG 1 (MoAbs no. 2-2, no. 2-3, no. 2-6, no. 2-10, and no. 2-11). Six clones were recovered that produced antibodies that recognized hNIS-14f (MoAbs no. 14f-2, no. 14f-5, no. 14f-6, no. 14f-7, no. 14f-9, no. 14f-10).
Iodide uptake COS-7 cells transiently transfected with the FL-hNIS cDNA clone in the pcDNA3 vector accumulated 23.45-fold more Na 125 I than cells transfected with the pcDNA3 vector alone (Fig. 2) . This uptake was inhibited by 10 m perchlorate, a known competitive inhibitor of thyroid iodine uptake (12) .
Western blotting analysis
Western blotting was performed to assess recognition of the recombinant hNIS protein in COS-7 membrane preparations by the monoclonal antibodies. MoAbs #hNIS-2-7 and 2-9 were not used for immunoblotting. Although all hNIS-2 IgG clones and all hNIS-14f recognized hNIS on western blotting, 2-2, 2-10, 2-11, 14f-5, 14f-6, and 14f-10 were the most sensitive ones (data not shown). The hNIS proteins were detected with monoclonal antibodies against hNIS 2-2 and monoclonals against hNIS-14f as a major broad band with molecular weight (MW) of approximately 97 kDa. Several minor bands with MW of 160 kDa, 68 kDa, 30 kDa, and 15 kDa were also visualized, all of which were specific for the hNIS-transfected cells (Fig. 3) . These bands disappeared when the monoclonal antibodies were preincubated overnight in the presence of the respective free peptides and recombinant hNIS, but not when incubated in the presence of control membrane (Fig. 4) .
Immunostaining of thyroid
Thyroid tissue from patients with Graves' disease incubated with monoclonal antibody against hNIS-14f showed the most intense immunostaining (Fig. 5A) , whereas no staining was observed in Graves' tissue incubated with commercial mouse IgG (Fig. 5B) , in nonthyroidal tissue (skin and endometrium) (Fig. 5, F-H) , or in Hü rthle cell cancer (Fig.  5D ). Intermediate staining was observed in papillary ( Figure  5E ) and follicular thyroid cancers (Fig. 5C ). The immunostaining was specific for the follicular epithelium and concentrated at the basolateral portion of the follicular cell membrane (Fig. 5, I-J) . The pattern of immunostaining in malignant cells was, in general, less intense and not well localized when compared to Graves' tissues (data not shown).
Discussion
We have generated monoclonal antibodies against the hNIS that are capable of recognizing this protein by ELISA, Western blotting, and immunohistochemistry with a high degree of specificity, and are the first such antibodies reported. Because of their activity, they will be highly useful in studies examining the expression and structure of NIS in thyroid cells and tissues. Further, because of their specificity, they should be helpful in defining the distribution of NIS outside the thyroid gland in tissues such as mammary gland (13) , gastric mucosa (13), salivary gland (14) , and others.
Western blotting of COS-7 membranes transfected with hNIS demonstrated a broad, major band of molecular weight (MW) 97 kDa and several other minor bands of MW approximately 160 kDa, 68kDa, 30kDa, and 15 kDa. These minor bands likely represent degradation fragments, although further studies are required to address this issue. The MW of 97 kDa is in agreement with the expected MW plus a significant carbohydrate component (14, 15) .
The results of the immunohistochemistry show that our antibodies are capable of recognizing hNIS with high specificity. The ability of these antibodies to stain different types of thyroid tissue with varying intensity is likely related to the variable expression of the protein in the different tissues. This is supported by the demonstration of very strong staining in several Graves' disease tissues, the less intense and more patchy staining in certain thyroid cancers, the absence of staining in Hurthle cell cancers, which are notorious for their frequent lack of ability to take up radioactive iodine (16, 17) , and the absence of immunostaining in several nonthyroidal tissues (Fig. 5) . In addition, the specificity of the antibody for the thyroid follicular cells is also demonstrated by the ability of our antibodies to recognize only follicular, rather than stromal cells, and by the fact that the strongest immunostaining is observed in the basolateral aspect of the follicular cell membrane, where the iodide symporter has been previously localized (13) .
In summary, we have generated monoclonal antibodies against the second ExMD, amino acids 37-54 of hNIS (hNIS-2), and the carboxy-terminus portion of hNIS, amino acids 625-643 (hNIS-14f), which are capable of recognizing this protein with high specificity and are useful for immunostaining of thyroid tissue. The degree of immunostaining likely correlates with the expression of this protein in different thyroid tissues. These antibodies will serve as important reagents in the study of the role of hNIS in the pathogenesis of benign and malignant thyroid disease. 
